BACKGROUND: Attacks of wheezing induced by upper respiratory viral infections are common in preschool children between the ages of 10 months and 6 years. A short course of oral prednisolone is widely used to treat preschool children with wheezing who present to a hospital, but there is conflicting evidence regarding its efficacy in this age group. METHODS: We conducted a randomized, double-blind, placebo-controlled trial comparing a 5-day course of oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children) withplacebo in 700 children between the ages of 10 months and 60 months. The children presented to three hospitals in England with an attack of wheezing associated with a viral infection; 687 children were included in the intention-to-treat analysis (343 in the prednisolone group and 344 in the placebo group). The primary outcome was the duration of hospitalization. Secondary outcomes were the score on the Preschool Respiratory Assessment Measure, albuterol use, and a 7-day symptom score. RESULTS: There was no significant difference in the duration of hospitalization between the placebo group and the prednisolone group (13.9 hours vs. 11.0 hours; ratio of geometric means, 0.90; 95% confidence interval, 0.77 to 1.05) or in the interval between hospital admission and signoff for discharge by a physician. In addition, there was no significant difference between the two study groups for any of the secondary outcomes or for the number of adverse events. CONCLUSIONS: In preschool children presenting to a hospital with mild-to-moderate wheezing associated with a viral infection, oralprednisolone was not superior to placebo. (Current Controlled Trials number, ISRCTN58363576.) 2009 Massachusetts Medical Society
RCT Entities:
BACKGROUND: Attacks of wheezing induced by upper respiratory viral infections are common in preschool children between the ages of 10 months and 6 years. A short course of oral prednisolone is widely used to treat preschool children with wheezing who present to a hospital, but there is conflicting evidence regarding its efficacy in this age group. METHODS: We conducted a randomized, double-blind, placebo-controlled trial comparing a 5-day course of oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children) with placebo in 700 children between the ages of 10 months and 60 months. The children presented to three hospitals in England with an attack of wheezing associated with a viral infection; 687 children were included in the intention-to-treat analysis (343 in the prednisolone group and 344 in the placebo group). The primary outcome was the duration of hospitalization. Secondary outcomes were the score on the Preschool Respiratory Assessment Measure, albuterol use, and a 7-day symptom score. RESULTS: There was no significant difference in the duration of hospitalization between the placebo group and the prednisolone group (13.9 hours vs. 11.0 hours; ratio of geometric means, 0.90; 95% confidence interval, 0.77 to 1.05) or in the interval between hospital admission and signoff for discharge by a physician. In addition, there was no significant difference between the two study groups for any of the secondary outcomes or for the number of adverse events. CONCLUSIONS: In preschool children presenting to a hospital with mild-to-moderate wheezing associated with a viral infection, oral prednisolone was not superior to placebo. (Current Controlled Trials number, ISRCTN58363576.) 2009 Massachusetts Medical Society
Authors: Juan Quevedo; Wallace Marsh; Jessica Yulfo; Olga Alvarez; Marcos Felici; Maria E Rojas Journal: P R Health Sci J Date: 2012-09 Impact factor: 0.705
Authors: Anab R Lehr; Martha L McKinney; Serge Gouin; Jean-Guy Blais; Martin V Pusic; Francine M Ducharme Journal: Can Respir J Date: 2013-09-17 Impact factor: 2.409
Authors: Avraham Beigelman; Tonya S King; David Mauger; Robert S Zeiger; Robert C Strunk; H William Kelly; Fernando D Martinez; Robert F Lemanske; Katherine Rivera-Spoljaric; Daniel J Jackson; Theresa Guilbert; Ronina Covar; Leonard B Bacharier Journal: J Allergy Clin Immunol Date: 2013-03-14 Impact factor: 10.793
Authors: Leonard B Bacharier; Theresa W Guilbert; David T Mauger; Susan Boehmer; Avraham Beigelman; Anne M Fitzpatrick; Daniel J Jackson; Sachin N Baxi; Mindy Benson; Carey-Ann D Burnham; Michael Cabana; Mario Castro; James F Chmiel; Ronina Covar; Michael Daines; Jonathan M Gaffin; Deborah Ann Gentile; Fernando Holguin; Elliot Israel; H William Kelly; Stephen C Lazarus; Robert F Lemanske; Ngoc Ly; Kelley Meade; Wayne Morgan; James Moy; Tod Olin; Stephen P Peters; Wanda Phipatanakul; Jacqueline A Pongracic; Hengameh H Raissy; Kristie Ross; William J Sheehan; Christine Sorkness; Stanley J Szefler; W Gerald Teague; Shannon Thyne; Fernando D Martinez Journal: JAMA Date: 2015-11-17 Impact factor: 56.272